1. Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation.

    Clinical Cancer Research 21(10):2338 (2015) PMID 25712682 PMCID PMC4433879

    The MUC1-C oncoprotein is an intracellular target that is druggable with cell-penetrating peptide inhibitors. However, development of peptidyl drugs for treating cancer has been a challenge because of unfavorable pharmacokinetic parameters and limited cell-penetrating capabilities. Encapsulation...
  2. Intracellular delivery of peptide cargos using iron oxide based nanoparticles: studies on antitumor efficacy of a BCL-2 converting peptide, NuBCP-9.

    Nanoscale 6(23):14473 (2014) PMID 25340469

    Delivering peptides into cells targeting the undruggable oncoproteins is an emerging area in cancer therapeutics. Here we report a novel nanoparticle-based delivery system that can transport therapeutic cargos to the intracellular sites without the need for a cell transduction or penetration dom...
  3. Intracellular delivery of peptide cargos using iron oxide based nanoparticles: studies on antitumor efficacy of a BCL-2 converting peptide, NuBCP-9.

    Nanoscale 6(23):14473 (2014) PMID 25340469

    Delivering peptides into cells targeting the undruggable oncoproteins is an emerging area in cancer therapeutics. Here we report a novel nanoparticle-based delivery system that can transport therapeutic cargos to the intracellular sites without the need for a cell transduction or penetration dom...
  4. Intracellular delivery of peptide cargos using iron oxide based nanoparticles: studies on antitumor efficacy of a BCL-2 converting peptide, NuBCP-9.

    Nanoscale 6(23):14473 (2014) PMID 25340469

    Delivering peptides into cells targeting the undruggable oncoproteins is an emerging area in cancer therapeutics. Here we report a novel nanoparticle-based delivery system that can transport therapeutic cargos to the intracellular sites without the need for a cell transduction or penetration dom...
  5. Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9.

    Cancer Research 74(12):3271 (2014) PMID 24741005 PMCID PMC4089982

    The preclinical development of peptidyl drugs for cancer treatment is hampered by their poor pharmacologic properties and cell penetrative capabilities in vivo. In this study, we report a nanoparticle-based formulation that overcomes these limitations, illustrating their utility in studies of th...
  6. Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9.

    Cancer Research 74(12):3271 (2014) PMID 24741005 PMCID PMC4089982

    The preclinical development of peptidyl drugs for cancer treatment is hampered by their poor pharmacologic properties and cell penetrative capabilities in vivo. In this study, we report a nanoparticle-based formulation that overcomes these limitations, illustrating their utility in studies of th...
  7. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

    Blood 123(5):734 (2014) PMID 24282218 PMCID PMC3907758

    Blasts from approximately one-third of patients with acute myeloid leukemia (AML) harbor activating mutations in the FMS-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase that confer a poor prognosis. The Mucin 1-C-terminal subunit (MUC1-C) oncoprotein is aberrantly expressed in AML blasts ...
  8. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

    Blood 123(5):734 (2014) PMID 24282218 PMCID PMC3907758

    Blasts from approximately one-third of patients with acute myeloid leukemia (AML) harbor activating mutations in the FMS-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase that confer a poor prognosis. The Mucin 1-C-terminal subunit (MUC1-C) oncoprotein is aberrantly expressed in AML blasts ...
  9. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

    Blood 123(5):734 (2014) PMID 24282218 PMCID PMC3907758

    Blasts from approximately one-third of patients with acute myeloid leukemia (AML) harbor activating mutations in the FMS-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase that confer a poor prognosis. The Mucin 1-C-terminal subunit (MUC1-C) oncoprotein is aberrantly expressed in AML blasts ...
  10. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

    Blood 123(5):734 (2014) PMID 24282218 PMCID PMC3907758

    Blasts from approximately one-third of patients with acute myeloid leukemia (AML) harbor activating mutations in the FMS-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase that confer a poor prognosis. The Mucin 1-C-terminal subunit (MUC1-C) oncoprotein is aberrantly expressed in AML blasts ...
  11. Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.

    Cancer Biology & Therapy 14(2):127 (2013) PMID 23114713 PMCID PMC3571994

    Mucin 1 (MUC1) is a heterodimeric glycoprotein that is aberrantly overexpressed in most human breast cancers. The oncogenic MUC1-C subunit promotes survival and blocks the apoptotic response to genotoxic anticancer agents. In the present studies, human MCF-7 and ZR-75-1 breast cancer cells were ...
  12. Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.

    Cancer Biology & Therapy 14(2):127 (2013) PMID 23114713 PMCID PMC3571994

    Mucin 1 (MUC1) is a heterodimeric glycoprotein that is aberrantly overexpressed in most human breast cancers. The oncogenic MUC1-C subunit promotes survival and blocks the apoptotic response to genotoxic anticancer agents. In the present studies, human MCF-7 and ZR-75-1 breast cancer cells were ...
  13. Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.

    Cancer Biology & Therapy 14(2):127 (2013) PMID 23114713 PMCID PMC3571994

    Mucin 1 (MUC1) is a heterodimeric glycoprotein that is aberrantly overexpressed in most human breast cancers. The oncogenic MUC1-C subunit promotes survival and blocks the apoptotic response to genotoxic anticancer agents. In the present studies, human MCF-7 and ZR-75-1 breast cancer cells were ...
  14. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells.

    Prostate 72(15):1659 (2012) PMID 22473899 PMCID PMC3413781

    The mucin 1 (MUC1) heterodimeric oncoprotein is overexpressed in human prostate cancers with aggressive pathologic and clinical features. However, few insights are available regarding the functional role of MUC1 in prostate cancer. Effects of MUC1-C on androgen receptor (AR) expression were dete...
  15. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells.

    Prostate 72(15):1659 (2012) PMID 22473899 PMCID PMC3413781

    The mucin 1 (MUC1) heterodimeric oncoprotein is overexpressed in human prostate cancers with aggressive pathologic and clinical features. However, few insights are available regarding the functional role of MUC1 in prostate cancer. Effects of MUC1-C on androgen receptor (AR) expression were dete...
  16. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.

    Genes & Cancer 3(7-8):503 (2012) PMID 23264850 PMCID PMC3527989

    Activation of the transcription factor STAT5 is essential for the pathogenesis of acute myelogenous leukemia (AML) containing the FLT3 internal tandem duplication (ITD) mutation. FLT3 ITD is a constitutively active tyrosine kinase that drives the activation of STAT5, leading to the growth and su...
  17. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.

    Genes & Cancer 3(7-8):503 (2012) PMID 23264850 PMCID PMC3527989

    Activation of the transcription factor STAT5 is essential for the pathogenesis of acute myelogenous leukemia (AML) containing the FLT3 internal tandem duplication (ITD) mutation. FLT3 ITD is a constitutively active tyrosine kinase that drives the activation of STAT5, leading to the growth and su...
  18. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.

    Genes & Cancer 3(7-8):503 (2012) PMID 23264850 PMCID PMC3527989

    Activation of the transcription factor STAT5 is essential for the pathogenesis of acute myelogenous leukemia (AML) containing the FLT3 internal tandem duplication (ITD) mutation. FLT3 ITD is a constitutively active tyrosine kinase that drives the activation of STAT5, leading to the growth and su...
  19. Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells.

    International Journal of Oncology 40(5):1643 (2012) PMID 22200620 PMCID PMC3326351

    The MUC1 heterodimeric protein is aberrantly overexpressed in diverse human carcinomas and contributes to the malignant phenotype. The MUC1-C transmembrane subunit contains a CQC motif in the cytoplasmic domain that has been implicated in the formation of dimers and in its oncogenic function. Th...
  20. Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells.

    International Journal of Oncology 40(5):1643 (2012) PMID 22200620 PMCID PMC3326351

    The MUC1 heterodimeric protein is aberrantly overexpressed in diverse human carcinomas and contributes to the malignant phenotype. The MUC1-C transmembrane subunit contains a CQC motif in the cytoplasmic domain that has been implicated in the formation of dimers and in its oncogenic function. Th...